Skip to main content
Neal Rosen, MD, Oncology, New York, NY

Neal L Rosen MD MD, PhD

[Pronunciation: Neal Rosen]

Breast Cancer, Gastrointestinal Cancer, Melanoma, Thoracic Cancer


Professor, Medicine, Weill Cornell Medical College

Request Appointment
  • 1275 York AvenueNew York, NY 10065

  • Book by Phone+1(231) 680-2242

Overview of  Dr. Rosen

Dr. Neal Rosen is an oncologist in New York, NY and is affiliated with Memorial Sloan Kettering Cancer Center. He received his medical degree from Albert Einstein College of Medicine of Yeshiva University and has been in practice 38 years. He is one of 510 doctors at Memorial Sloan Kettering Cancer Center who specialize in Oncology. He has more than 100 publications and over 500 citings.

Education & Training

  • National Institutes of Health Clinical Center
    National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1982 - 1985
  • Mass General Brigham/Brigham and Women's Hospital
    Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 1979 - 1982
  • Albert Einstein College of Medicine
    Albert Einstein College of MedicineClass of 1979

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 1991 - 2026
  • MD State Medical License
    MD State Medical License 1982 - 1987
  • Internal Medicine
    American Board of Internal Medicine Internal Medicine
  • Medical Oncology
    American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Efficacy of MEK Inhibition in Patients with Histiocytic Neoplasms  
    Robert J Young, Mario Lacouture, Neal Rosen, David M Hyman, Raajit Rampal, Gary A Ulaner, Benjamin H Durham, Lynn A Brody, Nature
  • Synergistic Anti-Angiogenic Treatment Effects by Dual FGFR1 and VEGFR1 Inhibition in FGFR1-Amplified Breast Cancer  
    Neal Rosen, MD, Nature

Press Mentions

  • Potential New Treatment for KRAS-GI2D Lung Cancer Reported in First-of-Its-Kind Clinical Trial
    Potential New Treatment for KRAS-GI2D Lung Cancer Reported in First-of-Its-Kind Clinical TrialApril 27th, 2025
  • Mechanisms of Resistance to KRAS Inhibitors Multiple and Diverse
    Mechanisms of Resistance to KRAS Inhibitors Multiple and DiverseJune 29th, 2021
  • Multiple Avenues Mapped for Resistance to Novel KRAS G12C Inhibitor
    Multiple Avenues Mapped for Resistance to Novel KRAS G12C InhibitorJune 24th, 2021
  • Join now to see all

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: